# Cellectis S.A. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Cellectis S.A.). ## Overview Cellectis S.A. is a clinical-stage biotechnology company focused on gene-editing technologies for cell and gene therapies. It develops allogeneic CAR T-cell cancer therapies and gene-therapy programs through a platform that combines research, engineering, and in-house manufacturing, with operations centered in Paris and additional sites in New York and Raleigh. ## Products & services • Gene-edited allogeneic CAR T-cell therapies • Cell and gene therapy discovery and development platform • In-house manufacturing for cell therapy programs • Gene-editing technologies and enabling tools • Clinical-stage oncology and therapeutic development programs - **Allogeneic CAR T therapies** (45%) — Off-the-shelf gene-edited CAR T-cell candidates designed for oncology treatment. - **Gene therapy platform** (25%) — Gene-editing programs and platform work applied to non-oncology therapeutic indications. - **Research and development services** (15%) — Internal discovery, engineering, and translational development supporting pipeline creation. - **Manufacturing and process development** (15%) — In-house cell and gene therapy manufacturing capabilities supporting clinical programs. - Gene-edited allogeneic CAR T-cell therapies - Cell and gene therapy discovery and development platform - In-house manufacturing for cell therapy programs - Gene-editing technologies and enabling tools - Clinical-stage oncology and therapeutic development programs ## Customers Cellectis primarily serves patients through its drug-development pipeline rather than selling commercial products to end markets. Its direct counterparties are typically biopharma partners, research collaborators, clinical investigators, and regulators involved in advancing cell and gene therapy programs. In practice, value creation depends on successful clinical development, manufacturing execution, and eventual partnering or commercialization. - **Oncology treatment programs** (primary) — Patients and treatment centers involved in CAR T-cell trials for cancer indications. - **Biopharma partners** (primary) — Companies that license, co-develop, or collaborate on gene-edited therapy assets. - **Research and clinical collaborators** (secondary) — Academic and clinical organizations supporting preclinical and trial development. - **Regulatory stakeholders** (secondary) — Agencies and ethics bodies that approve or monitor clinical and manufacturing activity. - Oncology patients targeted by CAR T-cell therapy programs - Biopharma partners seeking gene-editing and cell therapy assets - Clinical investigators and trial sites running studies - Research collaborators using the platform for therapeutic development - Regulatory authorities reviewing clinical and manufacturing data ## Geography Cellectis is headquartered in Paris, France, with operating locations in New York and Raleigh, North Carolina. The business is inherently international because research, clinical development, manufacturing, and investor access span Europe and the United States, and the company is listed in both the U.S. and France. - Headquartered in Paris, France - Operations and personnel in New York and Raleigh, NC - Listed on Nasdaq and Euronext Growth - Clinical and research activity spans Europe and the U.S. - International structure supports global partnering and capital access ## Strategy Cellectis’ strategy centers on using gene editing to build off-the-shelf CAR T-cell therapies and a broader therapeutic platform. A key strategic differentiator is its end-to-end control of development and manufacturing, which can support product quality, process control, and translational speed across the value chain. - **Advance clinical-stage CAR T assets** (short-term) — Clinical proof-of-concept is central to pipeline value in cell therapy. - **Expand gene-therapy applications** (medium-term) — Diversifies the platform beyond oncology and broadens commercial optionality. - **Maintain manufacturing control** (medium-term) — Process consistency and supply reliability are critical in complex cell therapies. - Advance allogeneic CAR T programs through clinical development - Extend gene-editing platform into additional therapeutic indications - Use in-house manufacturing to retain process control - Pursue partnerships and collaborations to broaden reach - Protect and leverage intellectual property around gene-editing methods ## Risks Cellectis faces the binary development risk typical of clinical-stage biotechnology companies, where trial outcomes, safety signals, and regulatory decisions can determine program value. It also has meaningful legal and intellectual-property exposure, along with manufacturing complexity and dependence on successful scale-up of advanced therapies. - **Clinical development failure** [critical] — Pipeline value depends on demonstrating safety and efficacy in human trials. - **Intellectual property disputes** [high] — The business relies on licensed and proprietary gene-editing rights. - **Manufacturing and scale-up risk** [high] — Cell therapies require tightly controlled production and release processes. - **Regulatory and approval risk** [high] — Advanced therapies require extensive review before and during trials. - Clinical trial failure could eliminate program value - Gene-editing and CAR T safety risks can delay development - Patent and licensing disputes may restrict technology rights - Manufacturing complexity can affect quality and supply - Regulatory requirements are stringent and time-consuming ## Accounting As a clinical-stage biotech company, Cellectis’ reported results are heavily affected by R&D expense recognition, stock-based compensation, and judgment around development-stage assets. Its financial statements also require careful assessment of intellectual-property contingencies, license arrangements, and the fair presentation of non-IFRS metrics alongside IFRS results. - **Research and development expenses** — High ongoing operating expense sensitivity - **Share-based compensation** — Affects adjusted versus IFRS earnings comparison - **License and patent contingencies** — Possible contingent liabilities or disclosure obligations - **IFRS 18 presentation changes** — Potential changes in presentation and subtotal disclosure - R&D expense timing drives reported operating loss - Stock-based compensation affects comparability between periods - License agreements can create contingent liabilities or rights issues - Non-IFRS adjusted income excludes non-cash compensation - IFRS 18 may change presentation and management-defined measures --- *Last updated: 2026-09-28T11:58:11.023178+00:00*